dc.contributor.author
Koppold-Liebscher, Daniela
dc.contributor.author
Kessler, Christian S.
dc.contributor.author
Steckhan, Nico
dc.contributor.author
Bähr, Vanessa
dc.contributor.author
Kempter, Cornelia
dc.contributor.author
Wischnewsky, Manfred
dc.contributor.author
Hübner, Marisa
dc.contributor.author
Kunz, Barbara
dc.contributor.author
Paul, Marion
dc.contributor.author
Zorn, Stefanie
dc.contributor.author
Sari, Sophia
dc.contributor.author
Jeitler, Michael
dc.contributor.author
Stange, Rainer
dc.contributor.author
Michalsen, Andreas
dc.date.accessioned
2022-05-27T10:27:10Z
dc.date.available
2022-05-27T10:27:10Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/35176
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-34893
dc.description.abstract
Background/objectives:
A few preliminary studies have documented the safety and feasibility of repeated short-term fasting in patients undergoing chemotherapy. However, there is a lack of data from larger randomized trials on the effects of short-term fasting on quality of life, reduction of side effects during chemotherapy, and a possible reduction of tumor progression. Moreover, no data is available on the effectiveness of fasting approaches compared to so-called healthy diets. We aim to investigate whether the potentially beneficial effects of short-term fasting can be confirmed in a larger randomized trial and can compare favorably to a plant-based wholefood diet.
Methods:
This is a multicenter, randomized, controlled, two-armed interventional study with a parallel group assignment. One hundred fifty patients, including 120 breast cancer patients and 30 patients with ovarian cancer, are to be randomized to one of two nutritional interventions accompanying chemotherapy: (1) repeated short-term fasting with a maximum energy supply of 350–400 kcal on fasting days or (2) repeated short-term normocaloric plant-based diet with restriction of refined carbohydrates. The primary outcome is disease-related quality of life, as assessed by the functional assessment of the chronic illness therapy measurement system. Secondary outcomes include changes in the Hospital Anxiety and Depression Score and as well as frequency and severity of chemotherapy-induced side effects based on the Common Terminology Criteria of Adverse Events. Explorative analysis in a subpopulation will compare histological complete remissions in patients with neoadjuvant treatments.
Discussion/planned outcomes:
Preclinical data and a small number of clinical studies suggest that repeated short-term fasting may reduce the side effects of chemotherapy, enhance quality of life, and eventually slow down tumor progression. Experimental research suggests that the effects of fasting may partly be caused by the restriction of animal protein and refined carbohydrates. This study is the first confirmatory, randomized controlled, clinical study, comparing the effects of short-term fasting to a short-term, plant-based, low-sugar diet during chemotherapy on quality of life and histological tumor remission.
Trial registration.
ClinicalTrials.gov NCT03162289. Registered on 22 May 2017
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Breast cancer
en
dc.subject
Ovarian cancer chemotherapy
en
dc.subject
Short-term fasting
en
dc.subject
Intermittent fasting
en
dc.subject
Plant-based nutrition
en
dc.subject
Caloric restriction
en
dc.subject
Randomized controlled trial
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
854
dcterms.bibliographicCitation.doi
10.1186/s13063-020-04700-9
dcterms.bibliographicCitation.journaltitle
Trials
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
21
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33059765
dcterms.isPartOf.eissn
1745-6215